PortfoliosLab logoPortfoliosLab logo
CORT vs. NVDA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CORT vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corcept Therapeutics Incorporated (CORT) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CORT achieves a 110.72% return, which is significantly higher than NVDA's 12.01% return. Over the past 10 years, CORT has underperformed NVDA with an annualized return of 29.33%, while NVDA has yielded a comparatively higher 68.47% annualized return.


CORT

1D
0.98%
1M
40.26%
YTD
110.72%
6M
-11.63%
1Y
5.36%
3Y*
46.50%
5Y*
27.35%
10Y*
29.33%

NVDA

1D
1.73%
1M
-2.94%
YTD
12.01%
6M
12.58%
1Y
47.43%
3Y*
75.35%
5Y*
64.54%
10Y*
68.47%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CORT vs. NVDA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CORT
Corcept Therapeutics Incorporated
110.72%-30.94%55.14%59.92%2.58%-24.31%116.20%-9.43%-26.02%148.76%
NVDA
NVIDIA Corporation
12.01%38.92%171.25%239.02%-50.26%125.48%122.30%76.94%-30.82%81.99%

Correlation

The correlation between CORT and NVDA is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.16

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Apr 14, 2004

0.19

Fundamentals

Market Cap

CORT:

$7.66B

NVDA:

$5.09T

EPS

CORT:

$0.41

NVDA:

$6.53

PE Ratio

CORT:

178.81

NVDA:

31.97

PEG Ratio

CORT:

89.07

NVDA:

0.18

PS Ratio

CORT:

11.07

NVDA:

20.13

PB Ratio

CORT:

12.00

NVDA:

26.03

Total Revenue (TTM)

CORT:

$769.10M

NVDA:

$253.49B

Gross Profit (TTM)

CORT:

$755.64M

NVDA:

$187.95B

EBITDA (TTM)

CORT:

$3.66M

NVDA:

$192.76B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CORT vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CORT
CORT Risk / Return Rank: 4747
Overall Rank
CORT Sharpe Ratio Rank: 4444
Sharpe Ratio Rank
CORT Sortino Ratio Rank: 4747
Sortino Ratio Rank
CORT Omega Ratio Rank: 5656
Omega Ratio Rank
CORT Calmar Ratio Rank: 4444
Calmar Ratio Rank
CORT Martin Ratio Rank: 4444
Martin Ratio Rank

NVDA
NVDA Risk / Return Rank: 7777
Overall Rank
NVDA Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
NVDA Sortino Ratio Rank: 7575
Sortino Ratio Rank
NVDA Omega Ratio Rank: 7373
Omega Ratio Rank
NVDA Calmar Ratio Rank: 7979
Calmar Ratio Rank
NVDA Martin Ratio Rank: 7979
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CORT vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CORTNVDADifference
Sharpe ratioReturn per unit of total volatility

-1.30

Sortino ratioReturn per unit of downside risk

-1.29

Omega ratioGain probability vs. loss probability

1.14

1.24

-0.10

Calmar ratioReturn relative to maximum drawdown

0.08

2.36

-2.27

Martin ratioReturn relative to average drawdown

0.15

5.73

-5.58

CORT vs. NVDA - Sharpe Ratio Comparison

The current CORT Sharpe Ratio is 0.07, which is lower than the NVDA Sharpe Ratio of 1.37. The chart below compares the historical Sharpe Ratios of CORT and NVDA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CORTNVDADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.07

1.37

-1.30

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.37

1.25

-0.89

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.44

1.38

-0.94

Sharpe Ratio (All Time)

Calculated using the full available price history

0.11

0.63

-0.51

Drawdowns

CORT vs. NVDA - Drawdown Comparison

The maximum CORT drawdown since its inception was -94.28%, which is greater than NVDA's maximum drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for CORT and NVDA.


Loading charts...

Drawdown Indicators


CORTNVDADifference

Max Drawdown

Largest peak-to-trough decline

-94.28%

-89.72%

-4.56%

Max Drawdown (1Y)

Largest decline over 1 year

-64.40%

-20.21%

-44.19%

Max Drawdown (3Y)

Largest decline over 3 years

-71.85%

-36.88%

-34.97%

Max Drawdown (5Y)

Largest decline over 5 years

-71.85%

-66.34%

-5.51%

Max Drawdown (10Y)

Largest decline over 10 years

-71.85%

-66.34%

-5.51%

Current Drawdown

Current decline from peak

-35.80%

-11.39%

-24.41%

Average Drawdown

Average peak-to-trough decline

-53.44%

-36.20%

-17.24%

Ulcer Index

Depth and duration of drawdowns from previous peaks

35.34%

8.30%

+27.04%

Volatility

CORT vs. NVDA - Volatility Comparison

Corcept Therapeutics Incorporated (CORT) has a higher volatility of 16.41% compared to NVIDIA Corporation (NVDA) at 13.14%. This indicates that CORT's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CORTNVDADifference

Volatility (1M)

Calculated over the trailing 1-month period

16.41%

13.14%

+3.27%

Volatility (6M)

Calculated over the trailing 6-month period

85.07%

26.37%

+58.70%

Volatility (1Y)

Calculated over the trailing 1-year period

76.73%

34.81%

+41.92%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

74.52%

51.75%

+22.77%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

67.22%

49.85%

+17.37%

Dividends

CORT vs. NVDA - Dividend Comparison

CORT has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.14%.


PositionTTM20252024202320222021202020192018201720162015
CORT
Corcept Therapeutics Incorporated
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVDA
NVIDIA Corporation
0.14%0.02%0.03%0.03%0.11%0.05%0.12%0.27%0.46%0.29%0.45%1.20%

Financials

CORT vs. NVDA - Financials Comparison

This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B20222023202420252026
164.90M
81.62B
(CORT) Total Revenue
(NVDA) Total Revenue
Values in USD except per share items

CORT vs. NVDA - Profitability Comparison

The chart below illustrates the profitability comparison between Corcept Therapeutics Incorporated and NVIDIA Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
98.3%
74.9%
Portfolio components
CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.

NVDA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported a gross profit of 61.16B and revenue of 81.62B. Therefore, the gross margin over that period was 74.9%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.

NVDA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported an operating income of 53.54B and revenue of 81.62B, resulting in an operating margin of 65.6%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.

NVDA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported a net income of 58.32B and revenue of 81.62B, resulting in a net margin of 71.5%.


Frequently Asked Questions


CORT and NVDA have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CORT has higher volatility (16.41%) compared to NVDA (13.14%). In terms of maximum drawdown, CORT dropped -94.28% vs NVDA's -89.72%.

NVDA currently has the higher Sharpe Ratio (1.37 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CORT and NVDA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer